Merck’s PD-1 Inhibitor Pembrolizumab Receives Fourth Lung Cancer Indication Approval in China
December 9, 2024
Source: drugdu
59
On December 3, Merck announced that its PD-1 inhibitor Pembrolizumab (brand name: Keytruda®) has been approved by the National Medical Products Administration (NMPA) in China for use in combination with platinum-based chemotherapy for neoadjuvant treatment, followed by continued use of Pembrolizumab as monotherapy for adjuvant treatment in patients with resectable stage II, IIIA, and IIIB non-small cell lung cancer (NSCLC). Previously, Pembrolizumab had received three indications for advanced non-small cell lung cancer in China.
https://finance.eastmoney.com/a/202412043259018786.html
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Yingtai Medical acquires Weiqiang Medical December 21, 2024
- 4 innovative medical devices approved for market launch December 21, 2024
- Once a month, potential “best-in-class” lipid-lowering drugs apply for listing December 21, 2024
- Notice! Xinma Pharmaceutical Recruitment and Procurement Involved in Bribery December 21, 2024
- New weight loss drug, the world’s first cAMP-biased GLP-1 agonist has been submitted for marketing December 21, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
